Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas

Autor: Panayiotis E. Pelargos, Seyed A. Hojat, Thien Nguyen, John P. Sheppard, Timothy F. Cloughesy, Lawrance K. Chung, Carlito Lagman, Linda M. Liau, Albert Lai, Robert M. Prins, Yu-Ling Chang, Joanna V. Demos, Isaac Yang, Ann M. Chan, William H. Yong, Lynn K. Gordon, Madhuri Wadehra, Leia Nghiemphu
Rok vydání: 2018
Předmět:
0301 basic medicine
Male
Cancer Research
Pathology
Neurology
Gene Expression
0302 clinical medicine
Epithelial membrane protein-2
80 and over
Molecular Targeted Therapy
Cancer
Aged
80 and over
Tissue microarray
Membrane Glycoproteins
Tumor
Brain Neoplasms
Hazard ratio
General Medicine
Glioma
Tissue Microarray Analysis
Middle Aged
Prognosis
Immunohistochemistry
Oncology
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
Adult
medicine.medical_specialty
Biology
Article
03 medical and health sciences
Rare Diseases
Biomarkers
Tumor
medicine
Humans
Neoplasm Staging
Aged
Neurology & Neurosurgery
Neurosciences
Biomarker
medicine.disease
nervous system diseases
Brain Disorders
Brain Cancer
030104 developmental biology
Ki-67 Antigen
Membrane protein
Tissue Array Analysis
Neurology (clinical)
Glioblastoma
Biomarkers
Zdroj: Brain tumor pathology, vol 35, iss 1
Popis: Epithelial membrane protein-2 (EMP2) expression is noted in many human cancers. We evaluated EMP2 as a biomarker in gliomas. A large tissue microarray of lower grade glioma (WHO grades II-III, n=19 patients) and glioblastoma (GBM) (WHO grade IV, n=50 patients) was stained for EMP2. EMP2 expression was dichotomized to low or high expression scores and correlated with clinical data. The mean EMP2 expression was 1.68 in lower grade gliomas versus 2.20 in GBMs (P=0.01). The percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas (90.0 vs. 52.6%, P=0.001). No significant difference was found between median survival among patients with GBM tumors exhibiting high EMP2 expression and survival of those with low EMP2 expression (8.38 vs. 10.98months, P=0.39). However, EMP2 expression ≥2 correlated with decreased survival (r=-0.39, P=0.001). The EMP2 expression level also correlated with Ki-67 positivity (r=0.34, P=0.008). The mortality hazard ratio for GBM patients with EMP2 score of 3 or higher was 1.92 (CI 0.69-5.30). Our findings suggest that elevated EMP2 expression is associated with GBM. With other biomarkers, EMP2 may have use as a molecular target for the diagnosis and treatment of gliomas.
Databáze: OpenAIRE
Externí odkaz: